Archives — Current Month (8)

Cannabis Biotech Stock Starting to Advance Again (12/15/2017)

A technical analysis by Clive Maund on CliveMaund.com has a Buy on this cannabis biotech stock.

more>

'The Market Gets it Wrong, Again'; Analyst Raises Target Price on Biotech (12/13/2017)

Ed Arce, an analyst with H.C. Wainwright & Co., explained the positive elements of this drug developer's recently released clinical trial data and why they did not warrant the market reaction they got.

more>

A New Breed of Regenerative Therapy Companies Taking Hold (12/07/2017)

A regenerative therapy company with expertise in both cell therapy development and manufacturing, and a potential treatment for diabetes, differentiates this company, says Hunter Diamond, CFA, CEO of Diamond Equity Research.

more>

Biotech Delivers 'Great' Phase 2 Data in NASH (12/07/2017)

John McCamant of the Medical Technology Stock Letter raised his target price on this company given the earning potential of a once-a-day oral treatment for liver disease in what could be a $35 billion market.

more>

Immuno-Oncology Candidate Yields 'Impressive' Early Clinical Results (12/06/2017)

This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts.

more>

Coverage Initiated on 'One of the Most Undervalued Biotech Companies in Canada' (12/06/2017)

David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm.

more>

Biotech Advances Potential 'Billion-Dollar Drug' with New Trial Launch in China (12/05/2017)

Maxim Group analyst Jason Kolbert discussed what the launch of a clinical trial in China means for this developer of immuno-oncology therapies.

more>

Drug in Combination with Merck's Blockbuster Keytruda Nearly Doubles Response Rate (12/04/2017)

Michael Sheikh, the founder of Falcon Strategic Research, delves into a biotech company whose trial results he believes could fuel takeover speculation.

more>

More Archives

2017Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2013Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2012Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe

Notable Quotes